| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
55,670,000 |
| Market
Cap: |
793.85(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.75 - $27.34 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Immunome is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics designed to change the way diseases are being treated. Co.'s primary focus areas are oncology and infectious disease. Co. is advancing two programs: a three-antibody cocktail (IMM-BCP-01) for potential treatment and prophylaxis of SARS-CoV-2, and an antibody (IMM-ONC-01) against interleukin 38, an immune checkpoint, for the potential treatment of various solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
211,504 |
211,504 |
| Total Buy Value |
$0 |
$0 |
$1,249,989 |
$1,249,989 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lapetina Bob |
PAO and VP Finance & Corporate |
• – – |
2024-01-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,047 |
|
30% |
|
| Bienaime Jean Jacques |
Director |
– • – |
2023-11-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,615 |
|
170% |
|
| Barchas Isaac |
Director |
– • – |
2023-10-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,712,328 |
|
182% |
|
| Barchas Isaac |
Director |
– • – |
2023-10-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
121,680 |
|
182% |
|
| Siegall Clay B |
President and CEOOfficer |
• • – |
2023-10-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
150,432 |
|
182% |
|
| Siegall Clay B |
President and CEO |
• • – |
2023-10-02 |
4 |
B |
$5.91 |
$999,996 |
D/D |
169,204 |
319,636 |
2.81 |
182% |
|
| Turner Bruce |
Chief Strategy Officer |
• – – |
2023-10-02 |
4 |
B |
$5.91 |
$249,993 |
D/D |
42,300 |
42,300 |
2.74 |
182% |
|
| Prendergast Franklyn G |
Director |
– • – |
2023-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
60,840 |
60,840 |
|
- |
|
| Rapp Michael |
Director |
– • – |
2023-10-02 |
4 |
A |
$5.91 |
$1,499,993 |
D/D |
253,806 |
1,071,172 |
|
- |
|
| Rapp Michael |
Director |
– • – |
2023-01-15 |
4 |
A |
$4.00 |
$70,000 |
D/D |
17,500 |
817,366 |
|
- |
|
| Lamattina John L |
Director |
– • – |
2023-01-15 |
4 |
A |
$4.00 |
$60,500 |
D/D |
15,125 |
66,953 |
|
- |
|
| Wagenheim Philip |
Director |
– • – |
2023-01-15 |
4 |
A |
$4.00 |
$35,000 |
D/D |
8,750 |
406,147 |
|
- |
|
| Lefenfeld Michael |
Director |
– • – |
2023-01-15 |
4 |
A |
$4.00 |
$55,500 |
D/D |
13,875 |
40,747 |
|
- |
|
| Rapp Michael |
Director |
– • – |
2021-09-13 |
4 |
B |
$19.96 |
$518,202 |
I/I |
25,962 |
208,742 |
2.1 |
-55% |
|
| Rapp Michael |
Director |
– • – |
2021-09-10 |
4 |
B |
$17.85 |
$276,675 |
I/I |
15,500 |
182,780 |
2.1 |
-58% |
|
| Rapp Michael |
Director |
– • – |
2021-09-09 |
4 |
B |
$17.44 |
$553,774 |
I/I |
30,450 |
167,280 |
2.1 |
-52% |
|
| Baron Richard A |
Director |
– • – |
2021-08-18 |
4 |
OE |
$11.38 |
$26,663 |
D/D |
2,343 |
2,343 |
|
- |
|
| Rapp Michael |
Director |
– • – |
2021-05-26 |
4 |
B |
$18.94 |
$43,562 |
I/I |
2,300 |
136,830 |
2.1 |
-7% |
|
| Lefenfeld Michael |
Director |
– • – |
2021-05-26 |
4 |
B |
$19.03 |
$25,405 |
D/D |
1,335 |
26,872 |
2.39 |
-7% |
|
| Rapp Michael |
Director |
– • – |
2021-05-25 |
4 |
B |
$18.32 |
$353,631 |
I/I |
19,303 |
134,530 |
2.1 |
9% |
|
| Sarma Purnanand D |
President and CEO |
• • – |
2021-05-25 |
4 |
B |
$18.41 |
$193,305 |
D/D |
10,500 |
10,500 |
2.81 |
9% |
|
| Lefenfeld Michael |
Director |
– • – |
2021-05-25 |
4 |
B |
$18.44 |
$50,065 |
D/D |
2,715 |
25,537 |
2.39 |
9% |
|
| Rapp Michael |
Director |
– • – |
2021-05-24 |
4 |
B |
$18.38 |
$586,230 |
I/I |
31,895 |
115,227 |
2.1 |
9% |
|
| Wagenheim Philip |
Director |
– • – |
2021-05-24 |
4 |
B |
$18.35 |
$247,725 |
D/D |
13,500 |
397,397 |
2.39 |
9% |
|
| Lefenfeld Michael |
Director |
– • – |
2021-05-24 |
4 |
B |
$17.80 |
$10,680 |
D/D |
600 |
22,822 |
2.39 |
9% |
|
35 Records found
|
|
Page 1 of 2 |
|
|
0.01 (0.07%) 
